Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Financial Results:
Glenmark Life Sciences Ltd reported Revenues for Q3FY24 of ₹564.00 Crores down from ₹855.00 Crore year on year, a fall of 34.04%.
Total Expenses for Q3FY24 of ₹465.00 Crores down from ₹543.00 Crores year on year, a fall of 14.36%.
Consolidated Net Profit of ₹117.00 Crores down 56.02% from ₹266.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹3.67, down 56.15% from ₹8.37 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.